Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency

StatusUnknown
PhaseNot specified
Started

Record status This record was last updated September 26, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist. Therefore, selective decision should be taken in patients in whom the two conditions coexist in the choice of drug and in the treatment of infections.The prevalence of the G-6-PD deficiency is high in SCD patients, but does not differ from that observed among non-SCD subjects .However, the G-6-PD deficiency appears to worsen the clinical features of SCD, there were more hospitalizations, major vaso-occlusive crises among G-6-PD deficient sickle cell patients.
Trial Details
NCT Number NCT06615024
Lead Sponsor Fatma Hussein Mahmoud
Conditions
(from sponsor)		 Sickle Cell Disease and G6PD Deficiency
Related terms Anemia, Sickle Cell, Glucosephosphate Dehydrogenase Deficiency
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov